Murat Kalayoglu - 02 Apr 2026 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Reporting relationship: 10%+ Owner
Issuer ticker: RNAC
Reported as of: 02 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Apr 2026, 16:28:06 UTC
Prior SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Murat Kalayoglu

Key filing fact

Murat Kalayoglu filed Form 4 for Cartesian Therapeutics, Inc. (RNAC) on 06 Apr 2026.

Key facts

This page summarizes Murat Kalayoglu's Form 4 filing for Cartesian Therapeutics, Inc. (RNAC).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Apr 2026, 16:28.

Change

Previous filing in this sequence was filed on 06 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002000002 Primary reporting owner

Kalayoglu Murat

Relationship: 10%+ Owner
Address: C/O SOAR BIO, LLC, 7144 13TH PL NW, WASHINGTON
Signature: /s/ Murat Kalayoglu
Signature date: 06 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RNAC transaction

Common Stock

Options Exercise

Transaction value
Shares: +758,001
Change %: +17%
Price
Shares after: 5,313,261
Date: 02 Apr 2026
Ownership: by trust
Footnotes: F1, F2

RNAC holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 506,999
Date: 02 Apr 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RNAC transaction Derivative

Series A Non-Voting Convertible Preferred Stock

Options Exercise

Transaction value
Shares: -22,740
Change %: -40%
Price
Shares after: 33,662
Date: 02 Apr 2026
Ownership: by trust
Underlying class: Common Stock
Underlying amount: 758,001
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On April 2, 2026, a trust (the "Trust") for the benefit of the reporting person's spouse and children elected to convert a portion of its shares of the issuer's Series A Non-Voting Convertible Preferred Stock into shares of the issuer's common stock. The remaining shares of the issuer's Series A Non-Voting Convertible Preferred Stock held by the Trust are subject to a beneficial ownership limitation.

Footnote F2

Shares are held by the Trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the Trust.

Footnote F3

On November 13, 2023, the issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023 (the "Merger"). These securities represent merger consideration payable as a result of the closing of the Merger and securities purchased in a private placement in November 2023.